When Immunotherapy Strikes the Brain: A Rare Case of Posterior Reversible Encephalopathy Syndrome after Nivolumab and Ipilimumab (P10-2.007)

Posterior reversible encephalopathy syndrome (PRES) is a neurological syndrome characterized by neurotoxic effects such as seizures, impaired vision, and headaches as well as vasogenic edema predominantly seen posteriorly on imaging. The advent of new immunotherapies in cancer patients has brought increased awareness to PRES, and a need for high clinical suspicion to expedite treatment of the underlying risk factors. We present a rare case of PRES following immunotherapy with Nivolumab and Ipilimumab.